Purpose
To describe a single institution experience with adrenal metastasectomy, and to elucidate factors that may bear prognostic significance.
Methods
Single center, retrospective review of patients with adrenal metastasis who underwent adrenalectomy performed with curative intent between 2000–2012. Kaplan-Meier method was utilized to evaluate overall survival from time of adrenalectomy to death or last follow-up. Primary endpoint was death from any cause. Clinical variables were examined for association with survival.
Results
Study included 62 patients with mean age of 60 (± 12) years. 55% (34/62) were male, 85% (53/62) presented with isolated adrenal metastasis, and 82% (51/62) had metachronous disease with median DFI of 22 months (range 6–217). Non-small cell lung cancer (NSCLC) was the most common primary comprising 50% of cases. Median survival for the study population was 30 months (range 1–145) and 5-year survival was 31%. Patients with NSCLC had significantly shortened survival compared to non-NSCLC with median and 5-yr survival of 17 vs. 47 months and 27% vs. 38%, respectively (p=0.033). Synchronous metastasis (p=0.028) and DFI <12 months (p=0.038) were also associated with worse survival outcome, though male gender (p=0.69) and oligometastatic disease (p=0.62) were not.
Conclusion
Adrenal metastasectomy resulted in median survival of 30 months and 5-year survival of 31%. Shorter survival was associated with lung primary, short disease-free interval, and synchronous metastasis, but not with the presence of oligometastatic disease provided that the primary cancer and additional metastatic lesions were adequately controlled and amenable to resection.